« Previous
Next »
Titles
- M10: bioanalytical method validation and study sample analysis : guidance for industry1
- M4 organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use1
- M4E(R2): the CTD--efficacy1
- M7(R1) assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk1
- M7(R2) assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk: guidance for industry1
- MEDLARS and health information policy1
- Magnetic resonance (MR) receive-only coil: performance criteria for safety and performance based pathway : guidance for industry and Food and Drug Administration staff1
- Making a little go a long way: the case of Sasha Bruce Youthwork1
- Making food and nutrition security a SNAP: recommendations for the 2023 Farm Bill1
- Management of suspected bacterial urinary tract infection in adults: a national clinical guideline1
- Manufacture of blood components using a pathogen reduction device in blood establishments: questions and answers1
- Manufacturers may need additional guidance to ensure consistent calculations of average sales prices1
- Manufacturers sharing patient-specific information from medical devices with patients upon request: guidance for industry and Food and Drug Administration staff1
- Manufacturing, supply chain, and drug and biological product inspections during COVID-19 public health emergency: questions and answers1
- Many Medicaid enrollees with opioid use disorder were treated with medication: however, disparities present concerns1
- Many Medicaid-enrolled children who were treated for ADHD did not receive recommended followup care1
- Marketing clearance of diagnostic ultrasound systems and transducers: guidance for industry and Food and Drug Administration staff1
- Marketing status notifications under Section 506I of the Federal Food, Drug, and Cosmetic Act: content and format1
- Marketplace coverage and economic benefits: key issues and evidence1
- Master protocols: efficient clinical trial design strategies to expedite development of oncology drugs and biologics1